TFF Pharmaceuticals to Participate in Anti-fungal Webinar Presented by Maxim Group LLC on September 17th, 2020
Panel discussion scheduled for Thursday, September 17, 2020 at 11:00 AM EDT
AUSTIN, Texas--(BUSINESS WIRE)-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, has been invited to present at a webinar titled A Too Quiet Pandemic – Fungal Disease, presented by Maxim Group LLC and M-Vest, on Thursday, September 17th, 2020.
Glenn Mattes, President & CEO of TFF Pharmaceuticals, and Dr. Dale Christensen, Director of Clinical Development at TFF Pharmaceuticals, will participate in a panel discussion led by Dr. Jason McCarthy, Maxim’s Senior Managing Director of Biotechnology Equity Research, along with other leading innovators in the fungal drug development space.
To access the presentation, please RSVP here. Following the conference, a live audio webcast of the panel discussion will be available on the Events page in the Investors section of the Company’s website. A recording of the panel will also be available for replay on the M-Vest platform.
- Panel Session Title: A Too Quiet Pandemic – Fungal Disease
- Data and Time: Thursday, September 17, 11:00 AM EDT
About TFF Pharmaceuticals’ Thin Film Freezing technology platform
TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology. allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.
This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the benefits of the Company’s TFF platform and its dry powder versions of Voriconazole and Tacrolimus and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of its dry powder versions of Voriconazole and Tacrolimus, (ii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (iv) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (v) those other risks disclosed in the section “Risk Factors” included in the Company’s 2019 Annual Report on Form 10-K filed with the SEC on March 26, 2020. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
President and CEO
TFF Pharmaceuticals, Inc.
Chief Financial Officer
TFF Pharmaceuticals, Inc.
Investor Relations and Media Contact:
Source: TFF Pharmaceuticals, Inc.